Group 1 - The stock of Giant Bio (02367.HK) increased by over 8% during the trading session, with a current rise of 7.03% to HKD 34.4 [1] - The trading volume reached HKD 256 million [1]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD, with a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first product aimed at improving cheek smoothness through a combined implant solution [1] - CICC expresses optimism regarding the approval of this product, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - Looking ahead, CICC believes that the company's research and development strength, brand recognition, and team cohesion remain solid, suggesting that there are opportunities for investment as the cosmetics market recovers and contributions from aesthetic medicine increase [1]

Group 1 - The core viewpoint of the article highlights that Giant Bio (02367) has seen a significant stock price increase, with a rise of over 8% during trading, currently at 34.4 HKD and a trading volume of 256 million HKD [1] - Giant Bio recently announced the approval of its "recombinant type I α1 collagen and sodium hyaluronate composite solution" as a Class III medical device, marking it as the world's first implant product aimed at improving cheek smoothness [1] - CICC expresses optimism regarding the product's approval, which is expected to further expand the company's aesthetic medicine product matrix and validate its leading technological research and development capabilities [1] Group 2 - The long-term outlook from CICC suggests that the company's research and development strength, brand recognition, and team cohesion remain solid [1] - As the cosmetics market recovers and the contribution from aesthetic medicine increases, CICC recommends paying attention to investment opportunities in the company [1]

2月5日早盘，港股市场多数板块调整，消费股逆势走强。截至10:10，中证港股通消费主题指数上涨 2.0%，成分股中，百胜中国涨超7%，巨子生物涨超5%，名创优品、泡泡玛特、毛戈平涨超4%。 市场分析认为，当前港股消费板块值得关注，一是因为9天超长春节假期有望带动黄金零售、酒旅、餐 饮等服务消费行情，而港股服务消费资产较为稀缺，有望在一季度受益；二是因为在前期持续回调后， 估值已进入低位水平，相关龙头公司近期的回购有望提振市场信息。 中证港股通消费主题指数覆盖酒旅、餐饮等传统服务业龙头，更包含潮玩、金饰等高成长资产，以及运 动服饰、白电等高股息标的，截至2月4日，指数滚动市盈率为17.9倍，位于2020年发布以来2.3%分位 处，股息率达3.6%。跟踪该指数的港股通消费ETF易方达（513070）管理费率仅为0.15%/年，是全市场 港股消费类ETF中唯一的低费率产品，助力投资者低成本布局港股消费龙头。 ...

Group 1 - The new consumption concept in Hong Kong stocks is showing active performance, with notable increases in companies such as Giant Bio (+5.54%), Mao Geping (+4.42%), Miniso (+3.92%), and Pop Mart (+3.79%) [2][3] - The State Council has issued a plan to accelerate the cultivation of new growth points in service consumption, focusing on enhancing key areas such as transportation, housekeeping, online audio-visual services, and inbound consumption [2][4] Group 2 - Pop Mart's new product series, PUCKY and Starry People, have gained significant popularity, with market estimates suggesting that the valuation of Pop Mart's IP potential is still underestimated [5] - Recent trends indicate that Pop Mart's new products are selling out on official websites and commanding high premiums on second-hand platforms, with hidden versions priced at 2-3 times and 3-6 times their original prices [5] - The cosmetics industry is projected to grow, with a retail sales increase of 6.18% year-on-year in 2023, as consumer spending stabilizes and the demand for product upgrades continues [5] Group 3 - The channel landscape is showing differentiated characteristics, with platforms like Douyin leading in sales and Tmall achieving its best growth in four years during the Double Eleven shopping festival [6] - Local brands are steadily increasing their market share, although market differentiation is intensifying, with companies like Anta, Pop Mart, and Haidilao identified as industry favorites for optional consumption [6][7] - Five major investment themes have been identified for 2026, focusing on emotional value consumption, health and wellness needs, the silver economy, emerging channel penetration, and multi-brand strategies [7]

Core Viewpoint - The consumer sector is experiencing a strong performance, particularly in the context of the Hong Kong Stock Connect Consumer ETF, which has seen significant inflows and notable gains in key stocks [1][5]. Group 1: Market Performance - The Hong Kong Stock Connect Consumer ETF (159268) has surged over 2%, with net inflows exceeding 46 million yuan over the past five days [1]. - Key stocks within the ETF include Baisheng China, which rose over 7%, and other notable performers like Giant Bio and Pop Mart, which increased by over 6% and 4% respectively [3][4]. Group 2: Company Earnings - Baisheng China reported a total revenue of $11.797 billion for the fiscal year 2025, marking a 4% year-on-year increase, with a net profit of $929 million, up 2% [3]. - In Q4 alone, Baisheng China achieved a revenue of $2.823 billion, reflecting a 9% increase year-on-year, and a net profit of $140 million, which is a 22% growth [3]. Group 3: Consumer Sector Insights - The consumer sector is showing a divergence in performance, with essential consumption industries experiencing a recovery while discretionary consumption faces challenges [8]. - The valuation of the consumer sector remains attractive, with the PE historical percentile for A-share food and beverage at 17%, indicating a slight increase from the previous month [9]. Group 4: Investment Trends - There is a notable shift in investment strategies, with international capital increasing its exposure to Chinese markets, particularly in consumer sectors [12]. - The report suggests focusing on leading brands in the liquor sector and those with improving fundamentals and dividend yields, such as dairy products and beer [14].

Company Summary - In January 2026, a total of 116 Hong Kong-listed companies initiated share buybacks, repurchasing 4.82 million shares for a total amount of 12.831 billion HKD, representing a 48.05% decrease compared to 24.699 billion HKD in the same period last year [1][2] - Tencent Holdings, Xiaomi Group, and Sunny Optical Technology were among the companies with the highest buyback amounts, with Xiaomi repurchasing shares worth 2.540 billion HKD and Sunny Optical repurchasing shares worth 1.016 billion HKD [1][3] - Other notable companies that executed significant buybacks include Geely Automobile, Pop Mart, and Giant Bio, each with buyback amounts exceeding 100 million HKD [1][2] Industry Summary - The majority of the companies initiating buybacks in January 2026 were concentrated in the software services and other healthcare sectors [4][5] - The software services industry led in both buyback amount and number of companies, with a total buyback amount of 6.720 billion HKD and 20 companies participating, including BaiRong Cloud and Youjia Innovation [4][5] - The other healthcare sector also had a significant presence, with 12 companies, including Giant Bio and Weigao Group, engaging in buybacks [5][6]

Company Summary - In January 2026, a total of 116 Hong Kong-listed companies initiated share buybacks, repurchasing 482 million shares for a total amount of 12.831 billion HKD, representing a 48.05% decrease compared to 24.699 billion HKD in the same period last year [1][2] - Notable companies with significant buyback amounts include Tencent Holdings, Xiaomi Group, Sunny Optical Technology, and Pop Mart, with Tencent repurchasing 10.205 million shares and spending 6.357 billion HKD [3][4] - Xiaomi Group repurchased 68.751 million shares for a total of 2.54 billion HKD, with a buyback price range between 34.92 HKD and 39.32 HKD per share [4][5] - Sunny Optical Technology repurchased 15 times in January, totaling 15.84 million shares and 1.016 billion HKD [5] - Pop Mart executed buybacks on January 19 and 21, acquiring 1.9 million shares for 348 million HKD, with a price range of 177.7 HKD to 194.9 HKD per share [5] Industry Summary - The companies initiating buybacks in January 2026 were primarily concentrated in the software services and other healthcare sectors [6][9] - The software services industry led in both buyback amount and number of companies, with a total buyback amount of 6.720 billion HKD and 20 companies participating, including Baidu Cloud and Youjia Innovation [7] - The other healthcare sector had 12 companies conducting buybacks, including Giant Bio and Weigao Group [9] - The pharmaceutical and biotechnology sectors also had a notable presence, with 12 companies, including Xiansheng Pharmaceutical and Shisi Pharmaceutical Group, engaging in buybacks [9]

Core Insights - Xi'an High-tech Zone has achieved steady economic growth since the 14th Five-Year Plan, with industrial output increasing from 203.5 billion to 421.1 billion, averaging a growth rate of 15% annually [1][2] Economic Performance - The industrial output of Xi'an High-tech Zone rose from 203.5 billion to 421.1 billion, with an annual growth rate of 15% [1] - The zone has ranked among the top ten in the national "High-Quality Development Top 100 Parks" for three consecutive years and is projected to be fifth in the national comprehensive evaluation of high-tech zones in 2024 [1] Technological Innovation - The zone has gathered advanced technologies, including femtosecond lasers and high-precision ground timing systems, and hosts the first national-level innovation platform in the new materials sector [2] - Over 6,000 national-level technology-based SMEs and high-tech enterprises have been cultivated, including 99 national-level specialized and innovative "little giant" enterprises [2] Industry Layout - Advanced manufacturing output has grown at an average rate of 15.6% during the 14th Five-Year Plan, with the digital economy's core industry scale surpassing 280 billion [2] - Emerging industries such as photonics, integrated circuits, new materials, and low-altitude economy are rapidly developing, with the photonics industry alone hosting 183 companies and generating over 20 billion in output [2] Key Sectors - The high-performance integrated circuit sector focuses on chip design and wafer manufacturing, leveraging leading companies like Samsung and ASE, and aims to create a world-class semiconductor industry cluster [2] - The high-end new materials sector, led by institutions like the Shaanxi Nonferrous Institute, aims to develop advanced rare metal materials and 3D printing materials [2] Low-altitude Economy - The low-altitude economy is centered around companies like Inno Aviation and Aerospace Power Research Institute, focusing on technologies such as turbofan engines and drone clusters [3] - The sector aims to establish a nationally influential low-altitude economic industrial cluster [3] High-end Medical Devices - The high-end medical device sector integrates technologies like 3D printing, photonics, and AI, collaborating with companies such as Juzhi Bio and Kangtuo Medical [3] - The goal is to create a comprehensive industrial base that facilitates the last mile of technology transfer [3] Support Measures - Five major support measures have been introduced to ensure the rapid growth of new tracks, including a dedicated mechanism for each track and annual funding of 100 million for future industries [3] - By 2028, the target for annual revenue growth in new tracks is set at 20%, aiming to strengthen technological breakthroughs and enterprise cultivation [3]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 巨子生物控股有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02367 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 5,000,000,000 | USD | | 0.00001 | USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF3 ...